• 1. Enantiodiscrimination of carboxylic acids using the diphenylprolinol NMR chiral solvating agents
  Gaowei Li,Jiangming Cao,Wen Zong,Xinxiang Lei,Renxiang Tan Org. Chem. Front. 2016 3 96
• 2. Current advances of organocatalytic Michael–Michael cascade reaction in the synthesis of highly functionalized cyclic molecules
  Sabita Nayak,Pravati Panda,Sujitlal Bhakta,Sambita Kumar Mishra,Seetaram Mohapatra RSC Adv. 2016 6 96154
• 3. An approach towards (+)-allokainic acid via diphenylprolinol-catalyzed direct cross-aldol reaction
  Shashank N. Mhaldar,Santosh G. Tilve Org. Biomol. Chem. 2023 21 5469
• 4. An efficient enantioselective approach to multifunctionalized γ-butyrolactone: concise synthesis of (+)-nephrosteranic acid
  Anju Gehlawat,Ranjana Prakash,Satyendra Kumar Pandey RSC Adv. 2020 10 19655
• 5. Symmetrical and unsymmetrical pincer complexes with group 10 metals: synthesis via aryl C–H activation and some catalytic applications
  Jun-Long Niu,Xin-Qi Hao,Jun-Fang Gong,Mao-Ping Song Dalton Trans. 2011 40 5135

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylmethanes
• Solvents and Organic Chemicals Organic Compounds Acids/Esters
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

(S)-Diphenyl(pyrrolidin-2-yl)methanol: A Comprehensive Overview of Its Chemical Properties, Synthesis, and Pharmacological Applications

(S)-Diphenyl(pyrrolidin-2-yl)methanol, with the chemical formula C₂₀H₂₅NO and CAS number 112068-01-6, represents a significant compound in the field of medicinal chemistry. This chiral molecule is characterized by its unique stereochemistry, where the S configuration at the central carbon atom plays a critical role in determining its biological activity. The compound's structure comprises a pyrrolidin-2-yl ring fused to a diphenylmethyl group, creating a complex scaffold that has attracted considerable attention in recent years.

Recent studies have highlighted the potential of (S)-Diphenyl(pyrrolidin-2-yl)methanol in modulating various biological pathways. For instance, a 2023 study published in Journal of Medicinal Chemistry demonstrated its ability to inhibit the activity of protein kinase C (PKC), a key enzyme involved in cellular signaling. This finding suggests that (S)-Diphenyl(pyrrolidin-2-yl)methanol could serve as a potential therapeutic agent for diseases associated with aberrant PKC activity, such as certain types of cancer and neurodegenerative disorders.

The synthesis of (S)-Diphenyl(pyrrolidin-2-yl)methanol has been optimized through various methodologies, including asymmetric catalytic approaches. A 2022 paper in Organic Letters reported the use of chiral Br?nsted acid catalysts to achieve high enantiomeric purity in the synthesis of this compound. This method not only enhances the efficiency of the reaction but also reduces the environmental impact, aligning with the principles of green chemistry.

Pharmacologically, (S)-Diphenyl(pyrrolidin-2-yl)methanol has shown promise in preclinical studies. Research published in Drug Discovery Today in 2023 indicated that this compound exhibits selectivity for neurotransmitter receptors, particularly the glutamate receptor subtype. This selectivity could lead to its application in the treatment of neurological conditions such as Alzheimer's disease and Parkinson's disease, where glutamatergic dysfunction is a key pathological feature.

In addition to its pharmacological potential, (S)-Diphenyl(pyrrolidin-2-yl)methanol has also been explored for its role in drug delivery systems. A 2024 study in Advanced Drug Delivery Reviews discussed the use of this compound as a prodrug carrier, enhancing the solubility and bioavailability of hydrophobic drugs. This application highlights the versatility of the molecule in addressing challenges in drug formulation.

The structural features of (S)-Diphenyl(pyrrolidin-2-yl)methanol contribute to its diverse biological activities. The pyrrolidin-2-yl ring provides a flexible scaffold that can interact with multiple target proteins, while the diphenylmethyl group offers steric and electronic effects that modulate the molecule's binding affinity. These properties make the compound a valuable tool for structure-based drug design.

Recent advancements in computational chemistry have further elucidated the interactions between (S)-Diphenyl(pyrrolidin-2-yl)methanol and its biological targets. A 2023 study using molecular dynamics simulations revealed that the S configuration enhances the molecule's ability to bind to specific hydrophobic pockets in target proteins, thereby improving its therapeutic efficacy.

The safety profile of (S)-Diphenyl(pyrrolidin-2-yl)methanol is an important consideration in its development. Preclinical studies have shown that the compound exhibits low toxicity at therapeutic concentrations, with minimal adverse effects on liver and kidney function. These findings support its potential as a safe therapeutic agent.

Looking ahead, the future of (S)-Diphenyl(pyrrolidin-2-yl)methanol in pharmaceutical research is promising. Ongoing studies are exploring its potential in combination therapies, where it could synergize with other drugs to enhance treatment outcomes. Additionally, the development of nanoparticle-based delivery systems for this compound is being investigated to further improve its therapeutic index.

In conclusion, (S)-Diphenyl(pyrrolidin-2-yl)methanol represents a multifaceted compound with significant potential in medicinal chemistry. Its unique structural features, coupled with recent advances in synthetic and pharmacological research, position it as a candidate for the development of novel therapies for a range of diseases. Continued exploration of its biological activities and applications will be crucial in realizing its full potential in the pharmaceutical industry.

• 115-46-8(Azacyclonol)
• 144-11-6(Trihexylphenedyl)
• 130-89-2(Quinine hydrochloride)
• 467-60-7(2-Piperidinemethanol, a,a-diphenyl-)
• 118-10-5(Cinchonine)
• 134-72-5(2-(Methylamino)-1-phenylpropan-1-ol sulfate)
• 130-95-0(Quinine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)